Posted by Michael Wonder on 12 Jan 2023
Medcura receives breakthrough device designation for its LifeGel absorbable surgical hemostat
13 January 2023 - Medcura announces that the US FDA has granted the coveted breakthrough device designation for its LifeGel absorbable surgical haemostat.
LifeGel is the first and only haemostatic agent to receive breakthrough device designation seeking a new and highly differentiated indication: in surgical procedures (except in ophthalmic and urological) as an adjunctive haemostatic device when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical.
